Maze Therapeutics develops small molecule drugs for kidney and metabolic diseases and has no approved products yet. MAZE reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 19 | Canaccord Genuity | Initiated | Buy | |
| Sep 23 | Citigroup | Initiated | Buy | |
| Sep 23 | Wedbush | Reiterated | Buy | |
| Aug 12 | BTIG | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in MAZE in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MAZE is in one of them and how their past MAZE trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MAZE in an article yet. Here's the latest on the wider market.
About Maze Therapeutics
Maze Therapeutics is a biopharmaceutical company based in South San Francisco, California. It develops small molecule oral drugs for patients with kidney and metabolic diseases, using human genetic data to identify targets and guide development. Its most advanced candidate is in clinical trials for a genetically defined form of chronic kidney disease, and a second candidate is being prepared for trials in a metabolic disorder and chronic kidney disease. The company has no approved products, and it has partnered some of its programs with other drugmakers.
- Headquarters
- South San Francisco, CA